Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00431054 · ClinicalTrials.gov registry record · Phase 1

Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

A Phase 1 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target

NCT00431054: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.

NCT00431054 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00431054, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target

Study Summary

The goal of this clinical research study is to find out if a combination treatment of perifosine and docetaxel will help shrink or slow the growth of cancer cells in recurrent ovarian cancer. The safety of this combination treatment will also be studied.

Interventions

  • DRUG Docetaxel
  • DRUG Perifosine

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2007-02
Est. Completion 2012-05
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00431054 record still lists

NCT00431054 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).

The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.

NCT00431054 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00431054 about?

NCT00431054 is a clinical study titled "Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer". The goal of this clinical research study is to find out if a combination treatment of perifosine and docetaxel will help shrink or slow the growth of cancer cells in recurrent ovarian cancer. The safety of this combination treatment will also be studied.

What is the current status of trial NCT00431054?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2007-02. Estimated completion is 2012-05.

What interventions are being tested in trial NCT00431054?

The interventions under investigation include: Docetaxel (DRUG), Perifosine (DRUG).

Who is sponsoring clinical trial NCT00431054?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00431054's enrollment target sits among peer trials

22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00431054, the US trial registry maintained by the National Library of Medicine. NCT00431054 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.